Landfar Bio-medicine Co., Ltd. Class A

As of June 30, 2026, Landfar Bio-medicine Co., Ltd. Class A carries a market capitalization of 2.38B, placing it among publicly traded companies globally. Its enterprise value stands at 2.37B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Landfar Bio-medicine Co., Ltd. Class A has 330.02M shares outstanding.

As of June 30, 2026, Landfar Bio-medicine Co., Ltd. Class A trades at a trailing price-to-earnings ratio of 83.92. The price-to-sales ratio is 3.61, and the price-to-book ratio stands at 8.74.

As of June 30, 2026, Landfar Bio-medicine Co., Ltd. Class A trades at an EV/EBITDA multiple of 199.67 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 3.61 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 199.67 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 2.37B versus a market cap of 2.38B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Landfar Bio-medicine Co., Ltd. Class A maintains a current ratio of 1.45, meaning it holds 1.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 60.45, indicating elevated leverage, while an interest coverage ratio of 2.17 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Landfar Bio-medicine Co., Ltd. Class A posted a return on equity (ROE) of 11.18, showing how much profit the company earns on every dollar of shareholder capital. Return on assets (ROA) stands at 3.82, measuring how efficiently the asset base is converted into earnings. The company generates approximately 1.98M in revenue per employee across its workforce of 331.50, a quick read on workforce productivity versus industry peers. Inventory turnover of 15.13 indicates how many times Landfar Bio-medicine Co., Ltd. Class A sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Landfar Bio-medicine Co., Ltd. Class A recorded an income tax benefit of -2.40M rather than an expense, typically from losses, carryforwards, or the release of a tax provision. Taxes are levied on pretax income of 12.12M, leaving 28.32M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 23, 2026, Landfar Bio-medicine Co., Ltd. Class A's stock has declined approximately 5.58% over the past 52 weeks. The 50-day moving average sits at 9.46, while the 200-day moving average is 9.06.

Over the twelve months ended June 30, 2026, Landfar Bio-medicine Co., Ltd. Class A generated 657.55M in revenue and converted that into 28.32M in net income, yielding earnings per share of 0.04. EBITDA reached 11.88M, while operating income came in at 33.12M.

As of June 30, 2026, Landfar Bio-medicine Co., Ltd. Class A holds 308.97M in cash and equivalents against 216.94M in total debt, resulting in a net debt position of -102.83M. Total book value stands at 271.74M, with working capital of 197.60M providing operational flexibility.

These figures cover the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Landfar Bio-medicine Co., Ltd. Class A posted a gross margin of 13.22, reflecting its pricing power and cost economics. The operating margin of 5.04 and net profit margin of 4.31 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, Landfar Bio-medicine Co., Ltd. Class A paid dividends of 0.01 per share. The dividend payout ratio of 317.22 exceeds 100%, meaning the company is distributing more than it earns and funding the dividend from cash reserves, asset sales, or borrowing, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield is negative at -8.73, meaning Landfar Bio-medicine Co., Ltd. Class A raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Landfar Bio-medicine Co., Ltd. Class A's most recent stock split took place on January 15, 2007 with a 10:13 split ratio.

As of June 30, 2026, Landfar Bio-medicine Co., Ltd. Class A has an Altman Z-Score of 3.07, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.